OBJECTIVE To determine whether increased elimination of gadobenate ion via the hepatobiliary pathway might compensate for reduced/absent elimination via the urinary pathway in the event of compromised renal function, as a possible protective mechanism against nephrogenic systemic fibrosis (NSF). METHODS 15 male Crl:CD(®) R(SD)Br rats (Charles River Italia, Como, Italy) randomized to three tre...

OBJECTIVE The objective of our study was to retrospectively review one institution's cases of nephrogenic systemic fibrosis (NSF), evaluate possible associated factors, determine the prevalence of NSF, and search for gadolinium in skin samples obtained from patients with NSF. MATERIALS AND METHODS A retrospective review of our dermatopathology database from 1997 to 2007 was performed to searc...

Nephrogenic ascites is a condition characterized by the presence of massive ascites in a patient with ESRD. Neither the exact cause nor the pathogenesis of ascites formation is clearly understood. Patients frequently present with hypertension, moderate to massive ascites, minimal extremity edema, cachexia, and a history of dialysis-associated hypotension. The ascitic fluid is typically an exuda...

BACKGROUND Nephrogenic ascites refers to the condition of refractory ascites of unknown aetiology and occurs mainly in patients with end-stage renal disease who are undergoing haemodialysis. Despite many treatment modalities, nephrogenic ascites remains difficult to control and has a poor prognosis. METHODS We investigated six such patients who had developed severe, apparently refractory asci...

BACKGROUND Nephrogenic systemic fibrosis (NSF) is a complication of the gadolinium-based contrast agent used in imaging studies. It is typically characterised by hard, erythematous and indurated skin plaques with surrounding subcutaneous oedema. Distinct papules and subcutaneous nodules can also be seen. Fibrocytes in NSF are immunohistochemically positive for CD34. CASE PRESENTATION We prese...

Purpose: Contrast-enhanced MR Angiography (CE-MRA) is a widely accepted technique for evaluation of the renal arteries; however, recent concerns regarding the development of nephrogenic systemic fibrosis (NSF) after gadolinium contrast agent administration in patients with reduced renal function have emphasized the need for robust non-contrast MRA methods. One such technique is steady state fre...

BACKGROUND The association of gadolinium-based contrast agents (GBCAs) with nephrogenic systemic fibrosis (NSF) has led to a heightened awareness towards patients' renal function. Whereas detailed guidelines exist for the use of GBCAs in adult patients, best practice is less well defined in children, especially in the very young. We aimed at identifying current practice with regards to the use ...

INTRODUCTION Recent studies have demonstrated a link between the use of gadolinium-based contrast agents and the development of nephrogenic systemic fibrosis (NSF) [1]. Given growing concerns of developing NSF, it has become important to investigate non-contrast methods of evaluating renal function. We have developed an MRI perfusion technique employing arterial spin labeling (ASL) [2] that all...

Nephrogenic systemic fibrosis is a progressive, potentially fatal multiorgan system fibrosing disease related to exposure of patients with renal failure to the gadolinium-based contrast agents used in magnetic resonance imaging. Because of this relationship between nephrogenic systemic fibrosis and gadolinium-based contrast agents, the U.S. Food and Drug Administration currently warns against u...

Gadolinium-based magnetic resonance (MR) contrast agents (GBCM) causes a devastating systemic fibrosing illness, nephrogenic systemic fibrosis (NSF), in patients with reduced kidney function. GBCM targets iron-recycling CD163- and ferroportin-expressing macrophages to release labile iron that mediates gadolinium toxicity and NSF. GBCA might similarly target iron-rich, ferroportin-expressing str...